Why Is AIM ImmunoTech Stock Gaining Today?

All NewsMarch 18, 2026

AIM ImmunoTech stock surges after Japan fully approved a patent covering Ampligen with checkpoint inhibitors, strengthening its cancer-treatment IP portfolio.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent